MedPath

The Effects of Risperidone and Olanzapine on Thinking

Phase 4
Completed
Conditions
Schizophrenia
Psychotic Disorders
Registration Number
NCT00108368
Lead Sponsor
US Department of Veterans Affairs
Brief Summary

The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition.

Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of social cognition, particularly affect perception and social perception.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Diagnosed with schizophrenia disorder by a DSM IV.
  • Competent to sign informed consent
  • No history of poor response to Risperdal and Zyprexa
  • No organic brain disease
Exclusion Criteria
  • Mental retardation or any chronic medical illness which results in the patient not being appropriate for a switch to Risperdal or Zyprexa.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

VA Greater Los Angeles Healthcare System

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath